{"id":36961,"date":"2025-06-01T07:00:00","date_gmt":"2025-06-01T07:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4700424_CN00424_0"},"modified":"2025-06-01T07:00:00","modified_gmt":"2025-06-01T07:00:00","slug":"inxmed-announces-promising-phase-ib-ii-clinical-data-for-ifebemtinib-kras-g12c-inhibitor-in-kras-g12c-mutant-solid-tumors-at-asco-2025","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=36961","title":{"rendered":"InxMed Announces Promising Phase Ib\/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025"},"content":{"rendered":"
\n

NANJING<\/span>, China<\/span><\/span>, June 1, 2025<\/span><\/span> \/PRNewswire\/ — InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib\/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtinib (IN10018), an oral focal adhesion kinase (FAK) inhibitor in combination with garsorasib (D-1533), an oral KRAS G12C inhibitor, in KRAS G12C mutant solid tumors.<\/p>\n

The clinical data presented at the 2025 ASCO Annual Meeting (Abstract #8629 | Poster Board #109) included results from two cohorts:<\/p>\n

    \n
  1. Durability follow-up data of the single-arm cohort in first-line KRAS G12C-mutant non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 expression, who received ifebemtinib + garsorasib treatment.<\/li>\n
  2. A randomized cohort in previously treated KRAS G12C-mutant colorectal cancer (CRC) patients comparing ifebemtinib+ garsorasib versus garsorasib monotherapy. <\/li>\n<\/ol>\n

    In NSCLC cohort, the combination of ifebemtinib and garsorasib, as a dual-oral, chemotherapy-free regimen, demonstrated compelling clinical benefit including high response rates and durable efficacy, regardless of PD-L1 expression, and in CRC cohort, the result showed clear add-on efficacy by ifebemtinib compared to KRAS inhibitor monotherapy.<\/p>\n

    Key <\/b>Highlights in First-line <\/b>NSCLC: Dual-Oral Regimen Shows Durable Efficacy<\/b> and Emerging Survival Benefit<\/b> <\/p>\n

    As of March 31, 2025<\/span>, 33 first-line NSCLC patients, regardless of PD-L1 expression, were enrolled and received the combination of ifebemtinib and garsorasib, with a median follow-up of 16.0 months. Previously the company has reported an Objective Response rate (ORR) of 90.3% (data presented at ESMO 2024). The follow-up data were now summarized as follows:  <\/p>\n